Vanta Bioscience Ltd
Fundamental Score
Vanta Bioscience Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of VANTABIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.81%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
11 factors identified
Below-Average Return on Equity (-37.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-11.58%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Revenue Contraction (-70.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-32.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Elevated Debt Levels (D/E: 1.59)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (-2.69x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-43.40 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Vanta Bioscience Ltd
About VANTABIO
Business Overview
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. It also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and packaging and labeling; and batch release pharmacopoeia tests, such as pyrogen testing, stability studies, and abnormal toxicity and impurity profiling. Further, the company provides services to medical device industry including cytotoxicity, intracutaneous/mucous membrane irritation, dermal sensitization, mutagenicity assays, acute systemic toxicity, and implantation tests. Additionally, it is involved in the provision of risk assessment services to evaluate the active pharmaceutical ingredients, excipients, extractable, leachables, and pharmaceutical impurities; and expert services to determine health-based exposure limits for permitted daily exposure or allowable daily exposure, including occupational exposure limits. The company offers its services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. Vanta Bioscience Limited was incorporated in 2016 and is based in Secunderabad, India.
Company Details
Key Leadership
VANTABIO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Vanta Bioscience Ltd (VANTABIO)?
As of 09 Feb 2026, 09:28 am IST, Vanta Bioscience Ltd (VANTABIO) is currently trading at ₹19.89. The stock has a market capitalization of ₹16.84 (Cr).
Is VANTABIO share price Overvalued or Undervalued?
VANTABIO is currently trading at a P/E ratio of 0.00x, compared to the industry average of 45.95x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Vanta Bioscience Ltd share price?
Key factors influencing VANTABIO's price include its quarterly earnings growth (Sales Growth: -70.87%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vanta Bioscience Ltd a good stock for long-term investment?
Vanta Bioscience Ltd shows a 5-year Profit Growth of N/A% and an ROE of -37.24%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.59 before investing.
How does Vanta Bioscience Ltd compare with its industry peers?
Vanta Bioscience Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare VANTABIO's P/E of 0.00x and ROE of -37.24% against the industry averages to determine its competitive standing.
What is the P/E ratio of VANTABIO and what does it mean?
VANTABIO has a P/E ratio of N/Ax compared to the industry average of 45.95x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is VANTABIO performing according to Bull Run's analysis?
VANTABIO has a Bull Run fundamental score of 7.2/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does VANTABIO belong to?
VANTABIO operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vanta Bioscience Ltd.
What is Return on Equity (ROE) and why is it important for VANTABIO?
VANTABIO has an ROE of -37.24%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Vanta Bioscience Ltd generates profits from shareholders' equity.
How is VANTABIO's debt-to-equity ratio and what does it indicate?
VANTABIO has a debt-to-equity ratio of 1.59, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is VANTABIO's dividend yield and is it a good dividend stock?
VANTABIO offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has VANTABIO grown over the past 5 years?
VANTABIO has achieved 5-year growth rates of: Sales Growth -32.27%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in VANTABIO and why does it matter?
Promoters hold 72.81% of VANTABIO shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is VANTABIO's market capitalization category?
VANTABIO has a market capitalization of ₹17 crores, placing it in the Small-cap category.
How volatile is VANTABIO stock?
VANTABIO has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for VANTABIO?
VANTABIO has a 52-week high of ₹N/A and low of ₹N/A.
What is VANTABIO's operating profit margin trend?
VANTABIO has a 5-year average Operating Profit Margin (OPM) of 5.69%, indicating the company's operational efficiency.
How is VANTABIO's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -70.87% and YoY Profit Growth of 12.08%.
What is the institutional holding pattern in VANTABIO?
VANTABIO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.